Sanofi $SNY Shares Sold by Truist Financial Corp

Truist Financial Corp lowered its stake in Sanofi (NASDAQ:SNY) by 3.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 576,811 shares of the company’s stock after selling 22,735 shares during the period. Truist Financial Corp’s holdings in Sanofi were worth $27,225,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Financial Consulate Inc. purchased a new stake in shares of Sanofi during the third quarter valued at $26,000. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi in the second quarter worth about $28,000. First Horizon Corp purchased a new position in shares of Sanofi in the third quarter worth approximately $33,000. Salomon & Ludwin LLC raised its holdings in shares of Sanofi by 1,046.3% during the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after acquiring an additional 701 shares during the period. Finally, Concord Wealth Partners lifted its position in shares of Sanofi by 510.3% in the 2nd quarter. Concord Wealth Partners now owns 885 shares of the company’s stock valued at $43,000 after acquiring an additional 740 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on SNY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. TD Cowen reissued a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.67.

Sanofi Stock Performance

NASDAQ:SNY opened at $46.20 on Friday. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $112.68 billion, a P/E ratio of 10.82, a price-to-earnings-growth ratio of 1.33 and a beta of 0.45. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The firm has a 50 day moving average of $48.18 and a 200-day moving average of $48.70.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.